Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of three dosages of NewGam in CIDP
2015-005443-14Phase 3Completed
- Sponsor
- Octapharma
- Start
- Apr 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of subcuvia in chronic inflammatory demyelinating polyneuropathy (CIDP) (3 arms), sponsored by Octapharma. Primary endpoint: Primary efficacy and safety outcomes comparing three NewGam dosage levels. Started Apr 2017; status: completed.
02
Drugs
subcuvia
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2015-005443-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005443-14.